Results 181 to 190 of about 181,485 (338)

Bilateral synchronous salivary gland tumors: report of three cases. [PDF]

open access: yesDiagn Pathol
van der Wal JE   +3 more
europepmc   +1 more source

Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The NTRK fusion gene is detected in most salivary gland secretory carcinomas. While tropomyosin receptor kinase (TRK) inhibitors are used for various solid tumors with the fusion gene, there are no reports regarding TRK inhibitor use for unresectable parotid gland carcinomas that subsequently shrink and become resectable.
Arisa Nagano   +11 more
wiley   +1 more source

Quad Shot—A Tertiary Hospital Experience With a Palliative Radiotherapy Regimen for Head and Neck Cancer

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Head and neck cancer patients often present with locally advanced disease. For some patients, palliative treatment schedules focused on symptom control are often preferred. Perhaps the most widely used of these is the so‐called Quad Shot (QS) regimen.
Eirini Nikolaidou   +5 more
wiley   +1 more source

Eleven-Year Incidence of Salivary Gland Tumors-A Retrospective, Single-Centered Study in Croatia. [PDF]

open access: yesClin Pract
Modrić A   +5 more
europepmc   +1 more source

Mechanisms of enhancer‐driven oncogene activation

open access: yesInternational Journal of Cancer, EarlyView.
Abstract An aggressive subtype of acute myeloid leukemia (AML) is caused by enhancer hijacking resulting in MECOM overexpression. Several chromosomal rearrangements can lead to this: the most common (inv(3)/t(3;3)) results in a hijacked GATA2 enhancer, and there are several atypical MECOM rearrangements involving enhancers from other hematopoietic ...
Joyce Vriend   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy